Loading
Cumberland Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 Sept 2025.
Cumberland Pharmaceuticals Inc: what insiders have been doing
This page follows insider dealings at Cumberland Pharmaceuticals Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Cumberland Pharmaceuticals Inc logged 18 filings by 6 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Compared with its exchange (5,816 companies, median 19 filings), a count of 18 filings is below the norm. Looking back to 2021, when coverage begins, insiders filed 109 purchases and no sales. The 10-K for the year ended 31 December 2025 shows 44.5 m USD of revenue and -2.8 m USD of net income.
No insider has bought Cumberland Pharmaceuticals Inc shares on the open market in the past twelve months. Typically, a trade is published a median of 28 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
223
Thresholds
n/a
Buy Volume
€22,083
109 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleA. J. Kazimi8 buys
Caroline Young8 buys
James Jones8 buys
Kenneth Krogulski8 buys
Since the insiders bought
- +98.2%Entry US$3.38 · Close at T+365 US$6.70
- +98.2%Entry US$3.38 · Close at T+365 US$6.70
- +98.2%Entry US$3.38 · Close at T+365 US$6.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,070 of 24,148 companies
34.8
score / 100
Value31
Quality39
FCF yld4.4%
Earn yld-2.6%
EV/EBITDA39.6x
ROE-14%
Gross mgn85%
Net mgn-6.4%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.80
Analyst consensus
Income statement
RevenueUS$44.5M
Gross profitUS$37.9M85% margin
EBITDAUS$3M7% margin
Net income-US$2.8M-24.6% margin
Valuation
P/Book6.7x
Beta0.10
Balance sheet & cash
Market capUS$116.9M
Total debtUS$10.2M
Free Cash FlowUS$4.8M
Debt / Equity28%
Profitability & ownership
ROE-14.4%
ROA-2.9%
% insiders41.6%
% institutions18.7%
Last declaration on 20 March 2026
Declarations223 total
1,800 shares@ US$2.8026.5% of flowCommon StockSEC:0001087294-26-000040:0
1,800 shares@ US$2.8018.1% of flowCommon StockSEC:0001087294-26-000039:0
1,800 shares@ US$2.8018.9% of flowCommon StockSEC:0001087294-26-000036:0
1,800 shares@ US$2.808.2% of flowCommon StockSEC:0001087294-26-000037:0
1,800 shares@ US$2.8017.8% of flowCommon StockSEC:0001632384-26-000002:0
5,845 shares@ US$3.065.3% of flowCommon StockSEC:0001628280-26-019514:0
4 shares@ US$2.360.0% of flowCommon StockSEC:0001087294-26-000008:0
18 shares@ US$2.360.2% of flowCommon StockSEC:0001087294-26-000006:0
124 shares@ US$2.360.5% of flowCommon StockSEC:0001087294-26-000002:0
18 shares@ US$2.360.0% of flowCommon StockSEC:0001087294-26-000004:0
13 shares@ US$2.800.1% of flowCommon StockSEC:0001490829-25-000007:0
13 shares@ US$2.800.0% of flowCommon StockSEC:0001087294-25-000027:0
68 shares@ US$2.800.3% of flowCommon StockSEC:0001087294-25-000025:0
6 shares@ US$2.800.1% of flowCommon StockSEC:0001087294-25-000029:0
68 shares@ US$3.310.4% of flowCommon StockSEC:0001695580-25-000004:0
6 shares@ US$3.310.1% of flowCommon StockSEC:0001684087-25-000008:0
13 shares@ US$3.310.0% of flowCommon StockSEC:0001075050-25-000006:0
13 shares@ US$3.310.2% of flowCommon StockSEC:0001490829-25-000005:0
4 shares@ US$3.540.1% of flowCommon StockSEC:0001684087-25-000004:0
12 shares@ US$3.540.2% of flowCommon StockSEC:0001087294-25-000008:0
12 shares@ US$3.540.0% of flowCommon StockSEC:0001087294-25-000007:0
62 shares@ US$3.540.4% of flowCommon StockSEC:0001087294-25-000006:0
68 shares@ US$3.440.4% of flowCommon StockSEC:0001628280-25-041983:0
Canonical exit: 30 Oct 2025 (T+90)
6 shares@ US$3.440.1% of flowCommon StockSEC:0001628280-25-041989:0
Canonical exit: 30 Oct 2025 (T+90)
13 shares@ US$3.440.2% of flowCommon StockSEC:0001628280-25-041987:0
Canonical exit: 30 Oct 2025 (T+90)
25 of 223 declarations
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company listed on the Nasdaq under the ticker CPIX, in the United States. Headquartered in Nashville, Tennessee, the company develops, acquires, and commercializes branded prescription medicines, with a strategy focused on therapeutic niches where unmet medical needs remain significant. For French-speaking investors in France, Belgium, or Switzerland, Cumberland fits the profile of a U.S. small/mid-cap healthcare company with a mix of commercial execution and targeted development, rather than a broad-platform biotech. The company was founded in the early 2000s and has built its business by acquiring rights to established brands, reviving growth in those assets, and maintaining a more selective early-stage development pipeline through its development affiliate. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm?utm_source=openai))
Cumberland’s core business is built around FDA-approved branded products used primarily in hospital settings, specialty care, and selected niche indications. The company also maintains development assets through Cumberland Emerging Technologies to help advance early-stage candidates. Products and assets referenced in recent filings and releases include Vibativ, Sancuso, and the ifetroban program. In competitive terms, Cumberland is positioned as an agile specialty pharma operator that seeks to monetize existing assets while creating value in indications with meaningful unmet medical need. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001087294/000108729426000020/cpix-20251231.htm?utm_source=openai))
Read moreShow less
Geographically, the group remains a U.S.-based business with headquarters in the United States, but it has an increasingly international footprint as it expands certain products and secures approvals outside its domestic market. Recent disclosures highlight new international approvals and continued portfolio progress. During 2025, Cumberland reported revenue growth and stronger operational execution; in 2026, it announced a major strategic transaction with an affiliate of Apotex to integrate its commercial business in exchange for $100 million, while sharpening its focus on orphan-drug candidates and higher-upside development programs. This is an important strategic inflection point, as it reduces the company’s dependence on mature commercial brands and increases capital available for the next phase of growth. ([investor.cumberlandpharma.com](https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-31-fourth-quarter-2025?utm_source=openai))
Overall, Cumberland Pharmaceuticals Inc. is a U.S.-listed specialty pharma company on the Nasdaq that combines marketed products, branded-asset management, and focused pipeline development. For international equity investors, the key appeal lies in its specialty pharmaceutical model, disciplined portfolio approach, and recent regulatory and strategic catalysts. The latest company communications point to improving operating momentum through 2025, followed by a significant repositioning in early 2026 around the company’s most promising assets. ([investor.cumberlandpharma.com](https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-31-fourth-quarter-2025?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
